ConductScience.org, home

Paper33337329

Hidradenitis suppurativa and adalimumab in the COVID-19 era.

Marzano AV and 23 others. Eur J Dermatol, 2020. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Hidradenitis suppurativa and adalimumab in the COVID-19 era. Papers, record 33337329. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33337329

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Hidradenitis suppurativa and adalimumab in the COVID-19 era.
PubMed
Journal
Eur J Dermatol
PubMed
Year
2020
PubMed
Publication types
Case Reports, Journal Article, Multicenter Study
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.46
iCite
Revised in PubMed
2021-03-04
PubMed

Authors24

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Marzano AVAngelo Valerio
2Moltrasio CChiara
3Genovese GGiovanni
4Muratori SSimona
5Dapavo PPaolo
6Fabbrocini GGabriella
7Patrizi AAnnalisa
8Sechi AAndrea
9Micali GGiuseppe
10Pellegrino MMichele
11Gisondi PPaolo
12Dini VValentina
13Bianchi LLuca
14Fania LLuca
15Offidani AAnnamaria
16Prignano FFrancesca
17Atzori LLaura
18Miraglia EEmanuele
19Cannavò SPSerafinella Patrizia
20Bettoli VVincenzo

Source PubMed

See all 24 authorsDownload CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AdalimumabMajor topic
COVID-19Major topic
Hidradenitis SuppurativaMajor topic
Adult
Aged
Female
Humans
Risk Assessment

Source PubMed

Download CSV of topics

References6

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127518661Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.N Engl J Med2016https://conductscience.org/library/papers/27518661PubMed
232403954Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy.J Dermatolog Treat2022https://conductscience.org/library/papers/32403954PubMed
332277351Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic.Am J Clin Dermatol2020https://conductscience.org/library/papers/32277351PubMed
432283230Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations.J Am Acad Dermatol2020https://conductscience.org/library/papers/32283230PubMed
532119111Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study.Br J Dermatol2021https://conductscience.org/library/papers/32119111PubMed
628636793Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.Br J Dermatol2017https://conductscience.org/library/papers/28636793PubMed

Download CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
34945136Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.J Clin Med2021https://conductscience.org/library/papers/34945136PubMed
34679208Low incidence of COVID-19 in hidradenitis suppurativa: How to interpret it?Exp Dermatol2022https://conductscience.org/library/papers/34679208PubMed
34446947Clinical Dermatology and COVID-19 Pandemic: Narrative Review.Indian J Dermatol2021https://conductscience.org/library/papers/34446947PubMed
34085330Anti-COVID-19 measurements for hidradenitis suppurativa patients.Exp Dermatol2021https://conductscience.org/library/papers/34085330PubMed
33936084How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group.Front Immunol2021https://conductscience.org/library/papers/33936084PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33337329

GET https://conductscience.org/api/papers/v1/33337329/authors?page=2